We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Apollo Hospitals Opens New Diabetes Clinics

By HospiMedica International staff writers
Posted on 16 Oct 2014
Apollo Hospitals (Kolkata, India) has partnered with pharmaceutical giant Sanofi (Paris, France) to improve access to treatment for diabetics.

The joint venture, to be named Apollo Sugar Clinics, will be a subsidiary of Apollo Health and Lifestyle, with Sanofi proposing to buy a 20% stake. More...
For the first phase of the venture, Apollo is in the process of establishing 50 clinics within the next two months, up from 28 at present. The clinics, pitched as a one-stop shop for diabetics, will offer packages to better manage the disease through higher medicine compliance, dietary and exercise regimens, and other lifestyle changes to better manage diabetes related complications.

“Over the years, Apollo Hospitals has benchmarked global best practices in quality healthcare delivery with stringent alignment to approved standards and protocols,” said Prathap Reddy, MD, chairman of Apollo Hospitals Group. “With the increasing burden of diabetes in our society, we need to act quickly and with a sense of purpose to arrest the disease from claiming more lives.”

“Sanofi has a heritage of nearly 100 years in developing treatments for diabetes and understands the impact that local expertise and innovative care models can have for patients who are managing their diabetes,” said Christopher Viehbacher, CEO of Sanofi. “We do clinical research in diabetes globally and can come up with the best medicines and products to manage or treat a medical condition. But this [the sugar clinics] will give us that context to try out evidence based approach in healthcare and find out ways to provide better healthcare at reduced costs.”

India is estimated to have over 65 million people with diabetes and 77.2 million people diagnosed as being pre-diabetics. An average diabetic in urban India spends about INR 30,000 (USD 500) per year on treatment, and the cost of late diagnosis of diabetes can mean the patient end up spending 10–18 times higher.

Sanofi has already attempted to enter the Indian diabetes market in 2013, when it launched the All Star, a low-cost, reusable insulin pen device that was developed to suit Indian conditions.

Related Links:

Apollo Hospitals
Sanofi



Gold Member
12-Channel ECG
CM1200B
New
Gold Member
Handheld Blood Glucose Analyzer
STAT-Site
New
Medical-Grade Display
HL2316SHTB
New
Resorbable Bovine Collagen Membrane
GenDerm
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Health IT

view channel
Photo courtesy of Adobe Stock

Automated System Classifies and Tracks Cardiogenic Shock Across Hospital Settings

Cardiogenic shock remains a difficult, time-sensitive emergency, with delayed identification driving poor outcomes and persistently high mortality. Many cases go undocumented even at advanced stages, hindering... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.